FRONTLINE PHASE II RITUXIMAB-POLATUZUMAB-GLOFITMAB (R-POLA-GLO) TRIAL DEMONSTRATES A MANAGEABLE SAFETY PROFILE AND HIGH RESPONSE RATES IN ELDERLY AND MEDICAL UNFIT PATIENTS WITH AGGRESSIVE LYMPHOMA